Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iSONEP in wet AMD
NCT01414153Phase 2Completed
- Sponsor
- Lpath Therapeutics
- Start
- Aug 2012
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sonepcizumab in exudative macular degeneration, sponsored by Lpath Therapeutics. Started Aug 2012; status: completed.
02
Drugs
sonepcizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT01414153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01414153.